Editas Medicine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

Gilmore O’Neill

CEOGilmore O’Neill

Employees

246

Employees246

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2013

Founded2013

Employees

246

Employees246

EDIT Key Statistics

Market cap

188.35M

Market cap188.35M

Price-Earnings ratio

-0.72

Price-Earnings ratio-0.72

Dividend yield

—

Dividend yield—

Average volume

3.21M

Average volume3.21M

High today

$2.31

High today$2.31

Low today

$2.11

Low today$2.11

Open price

$2.16

Open price$2.16

Volume

1.75M

Volume1.75M

52 Week high

$6.05

52 Week high$6.05

52 Week low

$0.9101

52 Week low$0.9101

Analyst ratings

50%

of 14 ratings

Buy

35.7%

Hold

50%

Sell

14.3%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

CRISPR

Intellia Therapeutics